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Abstract
Background Compliance aids are devices which have been developed and are currently
used to assist individuals in their medicines management. The use of compliance aids
involves the transfer of medicines from the manufacturers’ original packaging and repack-
aged into an multicompartment compliance aid (MCA). MCAs do not guarantee the same
level of protection compared to manufacturer’s original packaging.
Objective The aim of this study was to investigate the stability proﬁle of atenolol,
aspirin and lansoprazole dosage forms repackaged together in two different commercially
available MCAs.
Methods In a laboratory in the United Kingdom, the physical stability of the formula-
tions repackaged into two commercially available brands of MCAs was evaluated. After
8 weeks of storage (under controlled ambient conditions), changes in the disintegration
(tablets only) and dissolution properties (all formulations) were examined in accordance
with British Pharmacopoeia (BP) speciﬁcations.
Key findings Findings from this study conﬁrm that changes in solid-dosage form qual-
ity are observed when repackaged into MCAs compared to manufacturers packaging
resulting in differences in in-vitro dissolution performance. However, even with these
changes, overall product performance was acceptable and within BP speciﬁcations.
Conclusion There is a need for greater collaboration in this area between manufacturers,
hospital and community pharmacists, academics and policymakers to increase the data
available on the physical stability and in turn performance of medicines repackaged into
MCAs.
Keywords compliance; multicompartment compliance aid; older patient; repackaging;
stability
Introduction
Compliance aids, also referred to as multicompartment compliance aids (MCAs) or dose
administration aids (DAAs), are devices which have been developed and are currently
used to assist individuals in their medicines management.[1] The rationale with most
MCAs is that one compartment corresponds to a single administration time-point and all
of the patient’s solid-dose medicines prescribed for that time-point are dispensed into that
compartment.[2–4] Where the frequency of administration does not exceed four times a
day, a 28-compartment MCA provides the patient with a 7-day dosing regimen for their
solid-dose medication.[2,3] Participants at a public engagement event in 2013 entitled
‘How to improve medicines for older people?[5] felt that although MCAs were widely
available to improve patient outcomes in terms of medicine management, these aids may
actually (in some cases) hinder compliance as oppose to improving it. This could occur
due to loss of contextual information on the appropriate use of their medicine when
received in an MCA, often leading to an inability to identify which drug is used to treat
their speciﬁc conditions. Some participants at the public engagement event had experi-
ence using automated medication dispensers (which have a self-locking shutter over the
lid preventing direct access to their medication except at the time the device was
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programmed for them to take their medication). These par-
ticipants expressed strong concern about not knowing how
they would cope if the system broke down.
The stability of a pharmaceutical product can be deﬁned
as ‘the capability of a particular medicine, in a speciﬁed
container, to remain within its physical, chemical, microbio-
logical, therapeutic and toxicological speciﬁcations’.[6] The
shelf life of a formulation is greatly affected by the intrinsic
stability of the active pharmaceutical ingredient (API), the
excipients, the potential interactions between them, the man-
ufacturing process, the packaging and environmental condi-
tions encountered during transport of the product and its
storage conditions.[7] Manufacturers’ packaging is speciﬁ-
cally designed to protect the medicinal product from envi-
ronmental factors encountered during storage, such as light,
air (oxygen, carbon dioxide and other gases), and moisture,
whilst also limiting the interactions between the dosage
form and the packaging material.[7–9] API stability within a
dosage form is routinely conﬁrmed according to interna-
tional regulatory requirements, where stability studies on
packaged medicines are conducted under long-term and
accelerated conditions at speciﬁc temperatures and relative
humidity (RH) to represent storage conditions experienced
in the distribution chain of the climatic zone(s) of the coun-
try or region of the world concerned.[10]
One of the main roles of manufacturers’ packaging is to
protect the product from exposure to conditions where phe-
nomena can occur that can alter its performance.[11] When a
solid material has a lower water activity than its surround-
ings, a process called deliquescence occurs, in which mois-
ture condenses on the solid resulting in a liquid condensate
which can dissolve the material.[12] This process will con-
tinue until the water activity of the dissolved material
matches that of its surroundings and can result in physical
and chemical change (e.g. appearance, dissolution and
degradation) of the material.[13]
The use of MCAs involves the transfer of medicines
from the manufacturer’s original packaging into the MCA.
The Royal Pharmaceutical Society (in the United Kingdom)
advises that ‘medicines should not be stored in a MCA for
longer than 8 weeks’[14] and have noted (along with Glass
and Haywood[7]) that there is a lack of sufﬁcient stability
data available to support the repackaging of medicines into
MCAs. Anecdotal (from both community and hospital phar-
macists) and literature evidence (such as from Haywood
et al.[15] and Perks et al.[16]) have shown that MCAs are
usually given as either a 1-, 4- or 8-week supply. Results
from a survey conducted by Church and Smith[3] of 392
repackaged drug products revealed that, although some
information regarding the potential stability of solid-dosage
forms in MCAs could be obtained from manufacturers,
there was still a lack of short-term stability data for the
transfer of drug products into these devices.[3] Manufactur-
ers, on the whole, discourage the repackaging of medica-
tions as there are little data available to support this
process.
Only a handful of medications have been investigated for
their stability following repackaging into MCAs, namely
metoprolol,[17] aspirin,[18] atenolol,[2] clozapine,[16]
furosemide,[19] paracetamol,[20,21] prochlorperazine[10] and
sodium valproate.[7,22]
Aim of the study
The physical stability of dosage forms repackaged into an
MCA and performance is an area of importance that has
been under-researched. Investigations into the chemical sta-
bility of the dosage forms were outside of the scope of this
study and were not conducted. The aim of this study was to
investigate the physical stability proﬁle of atenolol, aspirin
and lansoprazole dosage forms repackaged together in two
different commercially available MCAs.
Formulations of atenolol, aspirin and lansoprazole were
investigated due to their physicochemical, stability and thera-
peutic applications. Atenolol (a beta-adrenoreceptor antago-
nist i.e. a beta-blocker) is used to treat hypertension, angina
and some arrhythmias. Atenolol is a light-sensitive compound
and is reported to be photoreactive when exposed to ultravio-
let A (UVA) and ultraviolet B (UVB) radiation.[23] Aspirin
(or acetylsalicylic acid) at low doses is prescribed for sec-
ondary prevention of thrombotic cerebrovascular and cardio-
vascular disease and following bypass surgery. Aspirin is
hygroscopic and is rapidly hydrolysed to salicylic acid (SA)
on exposure to moisture (according to the British Pharma-
copoeia (BP), the limit of the SA content within a dispersible
aspirin tablets is 3%).[24] Lansoprazole (a proton pump inhibi-
tor (PPI)) is used for the treatment of duodenal and stomach
ulcer, heartburn, acid regurgitation, Zollinger–Ellison syn-
drome and the treatment or prevention of gastro-oesophageal
reﬂux disease and duodenal or stomach ulcer caused by Non-
Steroidal Anti-Inﬂammatory Drugs (NSAIDs).
Ethics approval
Ethics approval was not required for this study.
Methods
Products
Atenolol 100 mg ﬁlm-coated (atenolol FC) tablets, aspirin
75 mg dispersible tablets (aspirin DT) and lansoprazole
30 mg gastro-resistant capsules (lansoprazole GR-C) were
used in this study and were used as received. Atenolol,
aspirin and lansoprazole powders were purchased from
Sigma-Aldrich (Gillingham, UK), Alfa Aesar (Heysham,
UK) and Cambridge Bioscience LTD (Cambridge, UK)
respectively. Drug powders were used as either purchased
or compressed into compacts.
Sample preparation
An appropriate number of atenolol FC, aspirin DT and lan-
soprazole GR-C were repackaged into two commercially
available brands of MCAs, referred to as MCA1 and
MCA2.
MCA1 consists of a plastic 28-cell chamber. The indi-
vidual chambers (~3 9 1.5 9 1.5 cm3) are ﬂexible and
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arranged into seven rows of four in each column covered
by an aluminium foil lid.
MCA2 consists of a hard plastic 28-compartment circular
tray. The volume of each compartment is 10 mL. MCA2 is
designed to be preprogrammed (up to 24 times daily), and
the tray rotates within the dispenser to the next chamber
containing the patient’s medication which is visible through
an aperture in the lid. The alarm signal sounds at prepro-
grammed time intervals.
Both systems were kept under controlled room tempera-
ture conditions (i.e. 20°C/40 %RH) for 8 weeks with the
drug powders stored concurrently stored in open Petri
dishes under the same conditions. The temperature of a
pharmacy must be maintained within a range compatible
with the storage of medication (below 25°C). The time
frame of 8 weeks was chosen based on policy recommenda-
tions, literature and anecdotal evidence.[3,14–16]
The physical stability of the repackaged formulations
was evaluated at week 0 and after 4 and 8 weeks of storage
by examining changes in the water content, disintegration
(tablets only) and dissolution properties (all formulations) in
accordance with the BP speciﬁcations. For the drug pow-
ders, water content and changes in the molecular structure,
chemical degradation and changes in solid state under con-
ditions were evaluated. This was to observe the changes (if
any) to the drug alone without the inﬂuence of excipients.
Tablet morphology
Changes in sample morphology were evaluated using a
FEITM Quanta 200F Field Emission scanning electron micro-
scope (SEM) FEI, (Hillsboro, Oregon, USA) Samples were
coated with 20 nm of gold under vacuum using a Quorum
Q150T Turbo-Pumped Sputter Coater Quorum Technologies
(Laughton, UK) with a ﬁlm thickness monitor unit. All
micrographs were taken at an acceleration voltage of 5 kV.
Water content determination using
thermogravimetric analysis
The RH inside packaging is assumed to always be in an
equilibrium state between its surroundings and the contained
product, with moisture transfer into or out of the package
being rate-limited.[11] The RH within an MCA is expected
to be different from that of the original manufacturer pack-
age as they are made of different materials.
Water content was determined using thermogravimetric
analysis (TGA). Two samples of each formulation were
ﬁnely ground using a pestle and mortar, and samples were
analysed in Perkin Elmer 40 lL 0.15-mm aluminium pans
with an accompanying pinholed lid at 10°C/min over a suit-
able temperature range using a TA instruments 2950 Hi-Res
TGA (TA instruments, New Castle, DE, USA).
In-vitro disintegration testing
In-vitro disintegration testing was conducted on atenolol FC
and aspirin DT in accordance with the BP speciﬁcations
(Appendix XII A. Disintegration). Six tablets per storage
condition and MCA type were placed separately in the six
cylinders of the disintegration apparatus (Pharma Test Dist
3, Hainburg, Germany. Distilled water was used as the med-
ium at 37  0.5°C and 25  0.5°C for atenolol FC and
aspirin DT respectively. Disintegration was recorded by the
operator as the time-point corresponding to the breakdown
of all six tablets.
In-vitro dissolution testing
In-vitro dissolution testing was conducted on atenolol FC,
aspirin DT and lansoprazole GR-C according to the BP
method (Appendix XII B. Dissolution) using Apparatus 2
(Paddle apparatus). For atenolol FC and aspirin DT, in-vitro
dissolution test was conducted in 900 mL of dissolution
media (37  0.5°C) at a basket rotational speed of 50 rpm.
Ten milliliters sample from each vessel was taken at speci-
ﬁed time intervals and replaced with an equal amount of the
fresh dissolution media. Six tablets per storage condition
per MCA were tested.
BP speciﬁcations state that ‘no more than 10% of the
API should be dissolved from GR-C formulations during
the acid stage of the dissolution test’. According to the BP,
the dissolution methodology for lansoprazole GR-C
involved two steps. In the ﬁrst step (referred to as the acid
stage), formulations were placed in 0.1 M hydrochloric acid
(HCl) for 2 h. The second step (referred to as the buffer
stage) occurring immediately after the acid stage in the
same vessel involved adjusting the pH to pH 6.8 and con-
tinuing the in-vitro dissolution test using the same parame-
ters as mentioned above.
To compare the dissolution performances between the
different systems in this study, the f2 equation (Eq. 1) was
used. The f2 equation is an independent model that mea-
sures the similarity in percentage between two proﬁles of
dissolution[25] usually for bioequivalence studies; f2 is a log-
arithmic reciprocal square-root-transformation of the square
error, which can be expressed by Equation 1
f2 ¼ 50 log 1þ 1n
 

Xn
t¼1
Rt  Ttð Þ2
" #0:5
 100
8<
:
9=
;;
(1)
where n is the number of time points, Rt is the percentage
of drug release of a reference batch at the time t, and Tt is
the percentage of drug released at the comparison batch at
time t. When f2 is >50 (i.e., 50–100), this indicates the
sameness or equivalence of the two compared proﬁles. Con-
versely, when f2 is <50, this suggests that the proﬁles are
different. In this study, the similarity factor was used as a
mathematical approach to assess differences in the dissolu-
tion proﬁles acquired.
Powder X-ray diffraction
Powder X-ray diffraction (PXRD) studies of drug powders
were conducted on a D/Max-BR diffractometer (RigaKu,
Tokyo Japan) with Cu-Ka radiation operating at 40 mV and
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30 mA over the suitable 2θ range for each API, a step size
of 0.02° at 2°/min. Diffractograms produced were analysed
using OriginPro 9.0.0.
Results
Repackaged formulations
Formulation morphology
Figures 1 and 2 show SEM images of the surface of ateno-
lol FC, aspirin DT and lansoprazole GR-C repackaged into
MCA1 and MCA2 stored at ambient conditions for 4 and
8 weeks. No clear changes in morphology were observed in
samples stored in either system after 4 and 8 weeks com-
pared to week 0.
Water content
TGA studies were conducted to determine the changes in
water content of atenolol FC, aspirin DT and lansoprazole
GR-C after repacking into MCA1 and MCA2 and stored
under controlled room conditions for 4 and 8 weeks. These
results are summarised in Table 1. For atenolol FC samples
(stored in both MCA 1 and 2), there was no statistical sig-
niﬁcant different in values from week 0 to 8. For lansopra-
zole GR-C samples stored in both MCAs, a statistically
signiﬁcant difference was observed (p < 0.05, Student’s t-
test) where a decrease in water content occurred between
week 0 and 4 followed by an increase in water content in
week 8. Finally, aspirin DT samples saw an increase
(p < 0.05, Student’s t-test) in water content from week 0 to
8. As aspirin is hygroscopic, it is likely to be susceptible to
undergo deliquescence with small variations of RH, running
the risk of hydrolysis of aspirin to SA.
In-vitro disintegration and in-vitro dissolution
testing
Overall, faster disintegration times for atenolol FC and
aspirin DT were observed after formulations were repack-
aged into MCA1 and MCA2 for 4 and 8 weeks at room
temperature (Table 2). Rapid disintegration and in turn rapid
drug dissolution can potentially affect dosage form perfor-
mance. Common disintegrants are considered to be chemi-
cally stable under any ‘normal storage’ conditions but can
be greatly affected by moisture uptake.[11]
British Pharmacopoeia dissolution criteria states that for
conventional-release formulations, at least 80% of the API
should be released within 45 min. Both atenolol FC and
aspirin DT formulations (Figure 3a–d) repackaged and
stored under ambient conditions in both MCA1 and MCA2
passed according to this criteria. However, a faster dissolu-
tion was observed in both formulations (in both MCA1 and
MCA2) compared to that observed at week 0.
The dissolution methodology for lansoprazole GR-C
involves two steps in accordance with BP 2013, the acid
step and buffer step. The criteria state that in the acid step,
no more than 10% of the API should be dissolved from the
GR-C formulation. For repackaged lansoprazole GR-C
stored in MCA1, after 4 and 8 weeks storage under ambient
conditions, ~13% and ~10% of API was dissolved in 2 h,
Figure 1 SEM images of atenolol FC, aspirin DT and lansoprazole GR-C repackaged into the MCA1 stored at ambient
conditions. DT, dispersible tablets; FC, ﬁlm-coated; GR-C, gastro-resistant capsules; MCA, multicompartment compliance
aids; SEM, scanning electron microscope.
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compared with ~5% at week 0 (p < 0.05, Student’s t-test). .
Whilst for repackaged lansoprazole GR-C stored in MCA2
after 4 and 8 weeks storage, <10% of the API was dis-
solved in 2 h. In the buffer stage, all lansoprazole GR-C
met the BP dissolution criteria for GR-C of at least 80%
drug released in 45 min. Data showed more drugs was
released in the ﬁrst 5 min from repackaged lansoprazole
GR-C stored in both MCA1 and MCA2 for 4 and 8 weeks
(Figure 3e,f) at 22.08% and 25.00 % compared to 7.71% at
week 0.
Figure 2 SEM images of atenolol FC, aspirin DT and lansoprazole GR-C repackaged into the MCA2 stored at ambient
conditions. DT, dispersible tablets; FC, ﬁlm-coated; GR-C, gastro-resistant capsules; MCA, multicompartment compliance
aids; SEM, scanning electron microscope.
Table 1 Water content (%) of atenolol FC, aspirin DT and lansoprazole GR-C at weeks 0, 4 and 8 after repacking into MCA1 and MCA2
Week 0 (%) Week 4 (%) Week 8 (%)
MCA 1 MCA 2 MCA 1 MCA 2
Atenolol FC 5.91  0.49 5.72  0.25 5.80  0.08 5.78  0.31 5.85  0.14
Aspirin DT 3.69  0.04 4.43  0.04 4.68  0.13 4.85  0.28 4.80  0.21
Lansoprazole GR-C 2.36  0.03 1.30  0.04 1.57  0.04 1.41  0.02 1.33  0.04
DT, dispersible tablets; FC, ﬁlm-coated; GR-C, gastro-resistant capsules; MCA, multicompartment compliance aids.
Table 2 Disintegration times for atenolol FC and aspirin DT at weeks 0, 4 and 8 after repacking MCA1 and MCA2
Week 0 (seconds) Week 4 (seconds) Week 8 (seconds)
MCA 1 MCA 2 MCA 1 MCA 2
Atenolol FC 154.83  7.78 81.17  3.87 81.83  0.08 104.50  5.36 96.33  0.14
Aspirin DT 45.50  7.40 32.00  5.48 31.5  0.13 40.67  8.36 42.33  0.21
DT, dispersible tablets; FC, ﬁlm-coated; MCA, multicompartment compliance aids.
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(a) (b)
(c) (d)
(e) (f)
Figure 3 Mean (n = 6) dissolution proﬁles of original at week 0 (black line) and repackaged in an MCA at week 4 (red
line) and 8 (blue line). Atenolol FC repackaged and stored in (a) MCA 1 and (b) MCA 2, aspirin DT repackaged and
stored in (c) MCA 1 and (b) MCA 2, lansoprazole GR C repackaged and stored in (e) MCA 1 and (f) MCA 2. Standard
deviation bars are not displayed because they are smaller than the symbol. DT, dispersible tablets, FC, ﬁlm-coated, GR-C,
gastroresistant capsules; MCA multicompartment compliance aids.
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In this study, the f2 equation was used as a mathematical
approach to assess differences in the dissolution proﬁles
acquired. The similarity factors (f2) for the dissolution pro-
ﬁles of the formulations after repackaging into MCA1 and
storage for 8 weeks compared to the time 0 dissolution pro-
ﬁles were 45, 79 and 65% for atenolol FC, aspirin DT and
lansoprazole GR-C, respectively. For MCA2, the equiva-
lent values were 43, 63 and 63%. These results suggest
that the dissolution proﬁles of atenolol FT change after
repackaging into either MCA1 or MCA2 and subsequent
storage for 8 weeks, whereas the dissolution proﬁles of both
aspirin DT and lansoprazole GR-C are still comparable with
the time 0 proﬁles.
Active pharmaceutical ingredient powders
Formulation morphology
Figure 4 shows SEM images of atenolol, aspirin and lanso-
prazole powders stored at ambient conditions. No clear
changes in morphology were observed in the samples at
week 8 compared with week 0.
Water content
Unlike repackaged (in both MCA1 and MCA2) atenolol FC
and lansoprazole GR-C dosage forms which saw a general
decrease in water content over 8-week storage, atenolol and
lansoprazole powders saw an increase in water content after
8 weeks of storage (Table 3).
Powder X-ray diffraction studies
Figure 5 shows the PXRD diffraction patterns of repack-
aged atenolol, aspirin and lansoprazole powders stored
under ambient conditions for 8 weeks. Changes in PXRD
diffraction peak positions and intensities were observed in
aspirin powders, suggestive of changes possibly associated
in bond arrangement or solid state (i.e. due to hydrolysis of
aspirin to SA), from week 0 and 8.
Discussion
The physical stability proﬁle (in accordance with the BP
speciﬁcation) of atenolol FC, aspirin DT and lansoprazole
GR-C repackaged together was investigated in two different
commercially available and most commonly used MCAs
and stored for 8 weeks (under controlled room conditions).
The physical stability of drug powders was also stored (un-
der the same conditions) for 8 weeks to observe the changes
(if any) to the drug alone without the inﬂuence of excipi-
ents.
No statistically signiﬁcant differences in water content
were observed for repackaged atenolol FC after 8 weeks of
storage; however, atenolol drug powders saw a signiﬁcant
increase in water content. For aspirin DT and lansoprazole
GR-C, statistically signiﬁcant differences were observed in
water content (i.e. increase for aspirin DT and decrease for
lansoprazole GR-C) with little change observed for corre-
sponding drug powders alone. These ﬁndings suggest that
the presence of excipients (including ﬁlm coat and capsule
shell) may inﬂuence the water uptake mechanisms within a
formulation, which in turn could have an impact on the
dosage form properties and performance. The in-vitro disin-
tegration and dissolution properties of repackaged formula-
tions were faster compared to week 0. Interestingly, the rate
of lansoprazole release from GR-C showed a different pro-
ﬁle in the acid stage with more of the drug being released
in weeks 4 and 8 compared to week 0. This resulted in
more drug being released in the early in-vitro dissolution
in buffer stage; however, overall irrespective of MCA
type, lansoprazole dosage forms at weeks 4 and 8 met BP
dissolution criteria (i.e. at least 80% of drug released in
45 min).
Findings from this study conﬁrm that changes in solid-
dosage form quality are observed when repackaged into
MCAs compared to manufacturers’ packaging resulting in
differences in in-vitro dissolution performance. Although
even with these changes, overall product performance was
Figure 4 Scanning electron microscope images of atenolol,
aspirin and lansoprazole powders at week 0 and after
8 weeks stored at ambient conditions.
Table 3 Water content (%) of atenolol, aspirin and lansoprazole
powders after weeks 0 and 8 storage in ambient conditions
Water content (%)
Week 0 Week 8
Atenolol 2.33  0.34 4.06  0.55
Aspirin 2.02  0.14 2.46  0.07
Lansoprazole 1.46  0.17 2.90  0.34
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Figure 5 Powder X-ray diffraction (PXRD) diffraction pattern of repackaged (a) atenolol powders stored under ambient
conditions for 8 weeks. (b) PXRD diffraction pattern of repackaged aspirin powders stored under ambient conditions for
8 weeks. (c) PXRD diffraction pattern of repackaged lansoprazole powders stored under ambient conditions for 8 weeks.
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acceptable, and within BP speciﬁcations, the chemical sta-
bility should be further investigated via thermal analysis
methods. Manufacturers’ generally discourage the repackag-
ing of medicines due to insufﬁcient data available to support
this process; however, the use of MCAs is common practice
in healthcare settings especially community. Repackaging of
a medication invalidates the stability guarantee of the manu-
facturer, and in most cases, the responsibility to prepare
MCAs falls to nursing staff, pharmacists or pharmacy
staff.[1,15]
There is a need for greater collaboration in this area
between manufacturers, hospital and community pharma-
cists, academics and policymakers to increase the data avail-
able so that more informed decisions can be made by the
healthcare team for the patients taking into account the
beneﬁt–risk associated with repackaging of medicines into
MCAs.
Conclusion
Overall, this study conﬁrmed that changes in atenolol, lan-
soprazole and aspirin dosage form quality occurred when
repackaged into MCAs resulting in differences in in-vitro
dissolution performance. Even with these changes however,
product performance was deemed acceptable and within BP
speciﬁcations. Due to the lack of sufﬁcient data available to
support the repackaging of medicines into MCAs, there is a
greater need for cross-disciplinary collaborations to increase
data available to ensure informed decisions can be made by
the healthcare team for patients which take into account the
beneﬁt–risk associated with MCAs.
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